Generated effect modifiers (GEM's) in randomized clinical trials

Biostatistics

Volumn 18, Issue 1, 2017, Pages 105-118

  Petkova, Eva ^a,b   Tarpey, Thaddeus ^a,c   Su, Zhe ^a   Ogden, R Todd ^d  

^a NEW YORK UNIVERSITY   (United States)

^b NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^c WRIGHT STATE UNIVERSITY   (United States)

^d Columbia University ^*  (United States)

Author keywords

Biosignature; Moderator; Precision medicine; Treatment decision; Value

Indexed keywords

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; FEMALE; HUMAN; MALE; PERSONALIZED MEDICINE; PREDICTOR VARIABLE; RANDOMIZED CONTROLLED TRIAL; SIMULATION; STATISTICAL MODEL; METHODOLOGY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICAL ANALYSIS; STATISTICS AND NUMERICAL DATA;

DATA INTERPRETATION, STATISTICAL; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PRECISION MEDICINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 85014565736     PISSN: 14654644     EISSN: 14684357     Source Type: Journal    
DOI: 10.1093/biostatistics/kxw035     Document Type: Article

References (27)

1. CIARLEGLIO, A., PETKOVA, E., TARPEY, T. AND OGDEN, R. T. (2015). Treatment decisions based on scalar and functional baseline covariates. Biometrics 71, 884-894.
2. EMURA, T., CHEN, Y.-H. AND CHEN, H.-Y. (2012). Survival prediction based on compound covariate under cox proportional hazards models. PLoS One 7, 247627.
3. FOLLMANN, D. A. AND PROSCHAN, M. A. (1999). A multivariate test of interaction for use in clinical trials. Biometrics 55, 1151-1155.
4. GAIL, M. AND SIMON, R. (1985). Testing for qualitative interactions between treatment effects and patient subsets. Biometrics 41, 361-372.
5. GUNTER, L., ZHU, J. AND MURPHY, S.A. (2011). Variable selection for qualitative interactions in presonalized medicine while controlling the family-wise error rate. Journal of Biopharmaceutical Statistics 21, 1063-1078.
6. KANG, C., JANES, H. AND HUANG, Y. (2014). Combining biomarkers to optimize patient treatment recommendations. Biometrics 70, 695-707.
7. KRAEMER, H. C. (2013). Discovering, comparing, and combining moderators of treatment on outcome after randomized clinical trials: a parametric approach. Statistics in Medicine 32, 1964-1973.
8. LABER, E. B. AND ZHAO, Y.-Q. (2015). Tree-based methods for individualized treatment regimes. Biometrika 102, 501-514.
9. LU, W., ZHANG, H. H. AND ZENG, D. (2011). Variable selection for optimal treatment decision. Statistical Methods in Medical Research 22, 493-504.
10. MCKEAGUE, I.W. AND QIAN, M. (2014). Estimation of treatment policies based on functional predictors. Statistica Sinica 24, 1461-1485.
11. MURPHY, S.A. (2003). Optimal dynamic treatment regimes (with discussion). Journal of the Royal Statistical Society, Series B 58, 331-366.
12. QIAN, M. AND MURPHY, S. (2011). Performance guarantees for individualized treatment rules. Annals of Statistics 39, 1180-1210.
13. ROBINS, J. M. (2004). Optimal structured nested models for optimal sequential decisions. In: P. J. Heagerty and D. Y. Lina (editors), Proceedings of the Second Seattle Symposium on Biostatistics. NewYork: Springer, pp. 189-326.
14. ROBINS, J., ORELLANA, L. AND ROTNIZKY, A. (2008). Estimation and extrapolation of optimal treatment and testing strategies. Statistics in Medicine 27, 4678-4721.
15. ROBINS, J. M., ROTNITZKY, A. AND ZHAO, L. P. (1994). Estimation of regression coefficients when some regressors are not always observed. Journal of the American Statistical Association 89, 846-866.
16. SONG, R., KOSOROK, M., ZENG, D., ZHAO, Y., LABER, E. B. AND YUAN, M. (2015). On sparse representation for optimal individualized treatment selection with penalized outcome weighted learning. Stat 4, 59-68.
17. SONG, X. AND PEPE, M. S. (2004). Evaluating markers for selecting a patient's treatment. Biometrics 60, 874-883.
18. TIAN, L. AND TIBSHIRANI, R. J. (2011). Adaptive index models for market-based risk stratification. Biostatistics 12, 68-86.
19. TUKEY, J.W. (1991). Use of many covariates in clinical trials. International Statistical Review 59, 123-137.
20. TUKEY, J.W. (1993). Tightening the clinical trial. Controlled Clinical Trials 14, 266-285.
21. WANG, R., SCHOENFELD, D. A., HOEPPNER, B. AND EVINS, A. E. (2015). Detecting treatment-covariate interactions using permutation methods. Statistics in Medicine 34, 2035-2047.
22. WANG, R. AND WARE, J. H. (2013). Detecting moderator effects using subgroup analyses. Prevention Science 14, 111-120.
23. WELLEK, S. (1997). Testing for absence of qualitative interactions between risk factors and treatment effect. Biometrical Journal 39, 809-821.
24. ZHANG, B., TSIATIS, A. A., DAVIDIAN, M., ZHANG, M. AND LABER, E. (2012a). Estimating optimal treatment regimes from classification perspective. Stat 1, 103-114.
25. ZHANG, B., TSIATIS, A. A., LABER, E. B. AND DAVIDIAN, M. (2012b). Arobust method for estimating optimal treatment regimes. Biometrics 68, 1010-1018.
26. ZHAO, Y., ZENG, D., RUSH, A. J. AND KOSOROK, M. P. (2012). Estimating individualized treatment rules using outcome weighted learning. Journal of the American Statistical Association 107, 1106-1118.
27. ZHAO, Y., ZHENG, D., LABER, E. B. AND KOSORROK, M. R. (2015). New statistical learning methods for estimating optimal dynamic treatment regimes. Journal of the American Statistical Association 110, 583-598.